SUBSCRIBE
SUBSCRIBE

Travere Therapeutics

NEWS
Drug Development
Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018
Retrophin, Inc. today announced that it will present new data examining the long-term effects of sparsentan in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN) Kidney Week 2018.
October 9, 2018
 · 
6 min read
Biotech Beach
Retrophin Announces Upcoming Presentations at the 15th International Symposium on IgA Nephropathy
Retrophin, Inc. today announced two upcoming presentations related to its development program for sparsentan in the treatment of IgA nephropathy
September 30, 2018
 · 
8 min read
Biotech Beach
Retrophin to Present at Upcoming October 2018 Investor Conferences
Retrophin, Inc. (NASDAQ: RTRX) today announced that the Company’s management team will present at the following upcoming investor conferences in October
September 19, 2018
 · 
1 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Job Trends
Retrophin to Close Down Cambridge Operations, Cut Jobs in Consolidation Move
March 9, 2017
 · 
2 min read
Business
Retrophin’s R&D Head Resigns to Helm Unnamed Biotech Startup
October 6, 2016
 · 
2 min read
Policy
Retrophin Sues Ousted CEO Martin Shkreli for $65 Million
August 17, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Former Retrophin CEO Nabs $90 Million for Startup Turing Pharma
August 10, 2015
 · 
3 min read
Business
Ousted Retrophin CEO Martin Shkreli Launches Turing
February 24, 2015
 · 
3 min read
Policy
More Trouble for Retrophin Founder
January 8, 2015
 · 
2 min read
Load More
JOBS
IN THE PRESS
Press Releases
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
January 14, 2026
 · 
16 min read
Press Releases
Travere Therapeutics Provides Corporate Update and 2026 Outlook
January 13, 2026
 · 
17 min read
Press Releases
Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
 · 
1 min read
Press Releases
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 11, 2025
December 12, 2025
 · 
1 min read
Press Releases
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 10, 2025
November 10, 2025
 · 
1 min read
Press Releases
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
November 7, 2025
 · 
18 min read
Press Releases
Travere Therapeutics to Participate at Upcoming Investor Conferences - November 4, 2025
November 4, 2025
 · 
1 min read
Press Releases
Travere Therapeutics Reports Third Quarter 2025 Financial Results
October 31, 2025
 · 
19 min read
Press Releases
Travere Therapeutics to Report Third Quarter 2025 Financial Results
October 23, 2025
 · 
1 min read
Press Releases
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
October 20, 2025
 · 
19 min read
Load More